

Amendment

In the Claims:

Please cancel claims 1-5 without prejudice or disclaimer.

Please add new claims 6-32 as follows.

6. (New) A medicinal composition for treating a bone-pathobolism, said composition comprising human osteoclastogenesis inhibitory factor (OCIF) protein or a homolog thereof and a polysaccharide.

7. (New) The medicinal composition of claim 6, wherein said human OCIF protein homolog is selected from the group consisting of: human OCIF2, human OCIF3, human OCIF4, human OCIF5, and combinations thereof.

8. (New) The medicinal composition of claim 6, wherein said polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, sulfated glucan, and combinations thereof.

9. (New) The medicinal composition of claim 6, wherein said polysaccharide is selected from the group consisting of: heparin, pectin, carreegeenan, dextran sulfate, and combinations thereof.

10. (New) The medicinal composition of claim 6, wherein said polysaccharide is selected from the group consisting of: heparin having a molecular weight of 3,000 to 6,000, and dextran sulfate having a molecular weight of 5,000 to 10,000.

11. (New) The medicinal composition of claim 6, wherein the weight ratio of human OCIF protein or homolog thereof to polysaccharide in said composition is at least about 1:4 OCIF or OCIF homolog : polysaccharide.

12. (New) The medicinal composition of claim 6, wherein said bone-pathobolism is selected from the group consisting of: osteoporsis, hypercalcemia, and chronic articular rheumatism.

13. (New) A method for enhancing the activity of a human osteoclastogenesis inhibitory factor (OCIF) protein or homolog thereof, said method comprising administering said human OCIF protein or homolog thereof to a subject in conjunction with an activity enhancing amount of a polysaccharide;

wherein the activity of said human OCIF protein or homolog thereof is enhanced relative to the activity of said human OCIF protein when administered in the absence of said polysaccharide.

14. (New) The method of claim 13, wherein said method comprises administering said human OCIF protein or homolog thereof to a subject in conjunction with an activity enhancing amount of a polysaccharide in the form of a medicinal composition comprising said human OCIF protein or homolog thereof and said polysaccharide.

15. (New) The method of claim 13, wherein said human OCIF protein homolog is selected from the group consisting of: human OCIF2, human OCIF3, human OCIF4, human OCIF5, and combinations thereof.

16. (New) The method of claim 13, wherein said polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, sulfated glucan, and combinations thereof.

17. (New) The method of claim 13, wherein said polysaccharide is selected from the group consisting of: heparin, pectin, carreeenan, dextran sulfate, and combinations thereof.

18. (New) The method of claim 13, wherein said polysaccharide is selected from the group consisting of: heparin having a molecular weight of 3,000 to 6,000, and dextran sulfate having a molecular weight of 5,000 to 10,000.

19. (New) The method of claim 13, wherein the weight ratio of human OCIF protein or homolog thereof to polysaccharide in said composition is at least about 1:4 OCIF or OCIF homolog : polysaccharide.

20. (New) A method of treating a bone-pathobolism comprising administering a composition comprising human osteoclastogenesis inhibitory factor (OCIF) protein or homolog thereof and a polysaccharide.

21. (New) The method of claim 20, wherein said human OCIF protein homolog is selected from the group consisting of: human OCIF2, human OCIF3, human OCIF4, human OCIF5, and combinations thereof.

22. (New) The method of claim 20, wherein said polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, sulfated glucan, and combinations thereof.

23. (New) The method of claim 20, wherein said polysaccharide is selected from the group consisting of: heparin, pectin, carreegeenan, dextran sulfate, and combinations thereof.

24. (New) The method of claim 20, wherein said polysaccharide is selected from the group consisting of: heparin having a molecular weight of 3,00 to 6,000, and dextran sulfate having a molecular weight of 5,000 to 10,000.

25. (New) The method of claim 20, wherein the weight ratio of human OCIF protein or homolog thereof to polysaccharide in said composition is at least about 1:4 OCIF/OCIF homolog : polysaccharide.

26. (New) A medicinal composition for treating a bone-pathobolism, said composition comprising non-precipitated human osteoclastogenesis inhibitory factor (OCIF) protein or a homolog thereof and a polysaccharide.

27. (New) The medicinal composition of claim 26, wherein said human OCIF protein homolog is selected from the group consisting of: human OCIF2, human OCIF3, human OCIF4, human OCIF5, and combinations thereof.

28. (New) The medicinal composition of claim 26, wherein said polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate,

heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, sulfated glucan, and combinations thereof.

29. (New) The medicinal composition of claim 26, wherein said polysaccharide is selected from the group consisting of: heparin, pectin, carageenan, dextran sulfate, and combinations thereof.

30. (New) The medicinal composition of claim 26, wherein said polysaccharide is selected from the group consisting of: heparin having a molecular weight of 3,000 to 6,000, and dextran sulfate having a molecular weight of 5,000 to 10,000.

31. (New) The medicinal composition of claim 26, wherein the weight ratio of human OCIF protein or homolog thereof to polysaccharide in said composition is at least about 1:4 OCIF or OCIF homolog : polysaccharide.

32. (New) The medicinal composition of claim 26, wherein said bone-pathobolism is selected from the group consisting of: osteoporsis, hypercalcemia, and chronic articular rheumatism.--